Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation

Ren Lin and Qifa Liu*

Abstract
Viral infections are important causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although most viral infections present with asymptomatic or subclinical manifestations, viruses may result in fatal complications in severe immunocompromised recipients. Reactivation of latent viruses, such as herpesviruses, is frequent during the immunosuppression that occurs with allo-HSCT. Viruses acquired from community, such as the respiratory and gastrointestinal viruses, are also important pathogens of post-transplant viral diseases. Currently, molecular diagnostic methods have replaced or supplemented traditional methods, such as viral culture and antigen detection, in diagnosis of viral infections. The utilization of polymerase chain reaction facilitates the early diagnosis. In view of lacking efficacious agents for treatment of viral diseases, prevention of viral infections is extremely valuable. Application of prophylactic strategies including preemptive therapy reduces viral infections and diseases. Adoptive cellular therapy for restoring virus-specific immunity is a promising method in the treatment of viral diseases.

Keywords: Viral infection, Allogeneic hematopoietic stem cell transplantation, Diagnosis, Treatment, Prevention

Background
Viral infections are common complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). With wide use of HLA-mismatch, unrelated and cord blood donors as alternative sources of hematopoietic stem cells, and anti-thymocyte globulin (ATG) as the standard prophylaxis of graft versus host disease (GVHD) in HLA-mismatch and unrelated donor transplantation, allo-HSCT recipients are at increasing risk for viral infections [1-5]. Fortunately, improvements in viral diagnostics, such as utilization of polymerase chain reaction (PCR)-based molecular diagnostic methods as replacement of traditional methods, facilitate the early diagnosis of viral infections [6-8]. And application of prophylactic and preemptive strategies limits the reactivation of latent viruses and development of viral diseases [9-11]. Immunotherapeutic strategies to restore virus-specific immunity, such as virus-specific cytotoxic T cells (CTL) and donor lymphocyte infusion (DLI), have been used for the treatment of viral diseases [12-14]. These developments improve outcomes of viral infections after allo-HSCT [15-17]. The aim of this article is to review the current concepts of diagnosis, prevention and treatment of viral diseases in the recipients of allo-HSCT. A brief overview will be followed by a detailed discussion on common viral diseases and viruses.

Epidemiology
In the recipients of allo-HSCT, the difference in the reported incidence is due in part to asymptomatic or subclinical manifestations in most of viral infections and the changing epidemiology of viruses as well as differences in diagnostic methods [18-23]. Till now, large-sampled epidemiological data on overall incidence of viral infections are absent in the recipients of allo-HSCT. The limited data show that community acquired respiratory viruses (CARVs) and herpesviruses are the most common pathogens [24-26]. Among the causes of CARVs respiratory tract infections, a preponderance of respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are reported, followed by influenza virus and human metapneumovirus (HMPV) [19,20,27]. In herpesvirus
family, the incidence of herpes simplex virus (HSV) and varicella zoster virus (VZV) infections as well as cytomegalovirus (CMV) diseases have significantly decreased because of the effective prophylaxis [24,25]. The reports on human herpes virus (HHV)-6 diseases are increasing in allo-HSCT recipients [28-32].

**Risk factors for viral infections**

In the recipients of allo-HSCT, most viral infections are opportunistic and closely related with immune status. Thus, factors influencing engraftment and immune reconstitution all potentially impact viral infections. Peripheral blood stem cell transplantation is associated with fewer viral infections than bone marrow and cord blood transplantation due to better hematopoietic and immune reconstitution [33-35]. Compared with HLA-match related transplantation, HLA-mismatch related and unrelated transplantation have an increasing risk of viral infections because immune reconstitution is delayed by the intensified GVHD prophylactic strategy, such as the use of ATG [18,36-38]. GVHD may delay immune reconstitution and is considered an independent risk factor of viral infections [36]. In addition, other factors, such as the serologic status of donors and recipients before transplantation as well as the age of recipients, may also affect the incidence of viral infections. For example, CMV-seronegative recipients receiving graft from CMV-seropositive donors are at high risk of CMV diseases [24]. Children are high-risk population of CARVs infections [26].

**Diagnostic strategies**

Generally, the diagnosis of viral diseases in immunocompetent individuals is based on clinical manifestations and laboratory examination. A definitive diagnosis requires detection of specific virus in specimens obtained from involved tissues and secretions as well as blood, or even histopathologic evidences. However, such a definitive diagnosis is frequently unnecessary or unavailable due to the risk associated with the invasive procedure (e.g. infection, bleeding) [25,39]. Thus, stratified diagnosis of viral infections and diseases based on diagnostic evidences is recommended [25,39]. The clinical manifestations of viral diseases in immunocompromised individuals, including transplant recipients may be different with the immunocompetent population [40]. For instance, fever does not always occur and the disseminated diseases are more common [24,25,39]. Meanwhile, viral diseases generally occur with or subsequently to other transplant complications such as bacterial and fungal infections [24,25]. For example, CMV gastrointestinal disease is particularly difficult to diagnose because it frequently presents together with gut GVHD, and diarrhea is the same symptom of these two transplant complications [24]. Therefore, in the recipients of allo-HSCT, the diagnosis of viral diseases mainly depends on laboratory examination.

Laboratory diagnostic methods mainly include viral culture, serologic testing, antigen and nucleic acid detection [6]. Table 1 showed the common methods used in diagnosis of viral infections. The golden standard for diagnosis of most viral diseases is finding of specific histopathological features and detection of virus in the involved tissues. However, biopsy is often infeasible in allo-HSCT recipients, considering that most viral diseases occur at the early stages of transplantation with concomitant thrombocytopenia or unstable vital sign. Viral culture is unsuitable in the early diagnosis because it routinely takes days to weeks and requires specific cell lines [41]. Serologic testing requires finding of progressive increasing in antibody to identify a recent infection. Unfortunately, transplant recipients are usually unable to mount sufficient antibody because of immunosuppression. Therefore, serology is less helpful for clinical decision in the recipients of allo-HSCT [24-26]. Techniques of antigen detection, including fluorescent antibody assays and enzyme immunoassays, are rapid diagnostic methods of which results can be available within hours. But the limitation of these methods is poor sensitivity compared with molecular techniques [26,42,43]. Application of PCR technique in the detection of viral nucleic acid rapidly develops the viral diagnostics [6]. In theory, any virus can potentially be detected by PCR. Now, real-time quantitative PCR (RQ-PCR) is replacing traditional gel-based PCR because it can reflect the changes of viral loads [7,44-47]. The availability of these modern diagnostic tools facilitates early diagnosis and timely intervention of viral infections. Currently, the diagnosis of viral infections in the recipients of allo-HSCT mainly relies on PCR-based methods. To investigate new or uncommon pathogens, electron microscopy or viral culture can be used. Although biopsy has the aforementioned problems and risk, it is still required in the diagnosis of some specific viral diseases, such as EBV-associated post-transplant lymphoproliferative disorder (PTLD) [25,48].

**Treatment strategies**

Although multiple strategies have been used [17,24-26,39], the treatment of viral diseases remains rather a challenge because few agents are available and efficacious. In the recipients of allo-HSCT, immunotherapeutic strategies to restore virus-specific immunity, such as reducing immunosuppressants, DLI and ex vivo generation of virus-specific CTL, are now advocated in the treatment of viral diseases [14,25,49]. However, reducing immunosuppressants is unfeasible in many patients due to potential risk of GVHD [24,25], and DLI is limited by unavailable stem cells.
cell donors and the risk of exacerbating GVHD [49]. Of note, these adoptive cellular therapies are only proven efficacious for a few viruses, such as CMV, EBV and adenovirus [12,50,51]. Early intervention has a dramatic influence upon survival and may reduce the extent of permanent injury in survivors [20,52,53]. For example, in patients with CARVs infections, treatment is more effective if started prior to development of lower respiratory tract infection (LRTI) or respiratory failure [26,54,55]. Our data showed that the patients with EBV fever without tissue involvement had better treatment response than those with end-organ diseases or PTLD [4].

Prophylaxis strategies

Since specific therapy is limited to only several antiviral agents, prevention of viral infections is crucial to reduce the incidence and mortality of viral diseases. According to the different periods of transplantation, the strategies might be divided to prophylaxis pre-transplantation, during transplantation and post-transplantation. Before transplantation, selection of virus-seronegative stem cell donors for seronegative recipients, and decreasing virus loads in virus-seropositive donors and recipients should be considered. During transplantation, the strategies of conditioning and GVHD prophylaxis should be chosen prudently to minimize the delay of immune reconstitution. After transplantation, prophylaxis should be performed throughout the risk period such as pre-engraftment and GVHD. The incidence of HSV and VZV infections has decreased from 80% to lower than 5% in the recipients of allo-HSCT receiving antiviral prophylaxis throughout the risk period [25,56]. Preemptive therapy for reactivation of some latent viruses, such as CMV and EBV has been demonstrated to reduce the progression of viral diseases [24,25]. Vaccination, such as Measles–Mumps–Rubella and VZV vaccine, seems useful to prevent corresponding viral infections [57,58]. Influenza virus vaccine is suggested to be given to the recipients prior to each influenza season [59].

Viral diseases after HSCT

Respiratory diseases

Respiratory diseases after HSCT are mainly caused by CARVs [60,61]. Other viruses, such as herpesviruses and adenovirus, may also result in respiratory infections [61,62]. Majority of the patients present with upper respiratory infection, and 18-44% of these patients may progress to lower respiratory infection with mortality of 23-50% [18-21,23,63]. The incidence of respiratory diseases after allo-HSCT ranges from 3.5% to 29% [20,64], and the incidence of viral pneumonia is 2.1-14% [4,20,64-66]. Typical clinical manifestations include fever, cough, myalgias. Dyspnea is an important symptom of viral pneumonia. Some of CARVs infections show a pronounced seasonality. For example, RSV and influenza virus reach a peak incidence during the winter and spring [19]. CARVs may also result in epidemic outbreak in the wards. Herpesvirus pneumonia is usually caused by reactivation of latent viruses which occurs in severe immunosuppression such as early period of transplantation and GVHD [2,67,68].

Encephalitis /meningitis

In immunocompetent individuals, herpesviruses are the most frequent pathogens in sporadic viral encephalitis/ meningitis. A retrospective study from Schmidt-Hieber et al. showed that viral encephalitis was mainly caused by human herpes virus (HHV) -6, followed by EBV, HSV, JC virus, CMV, VZV in the recipients of allo-HSCT [69]. Our data showed that herpesvirus-associated encephalitis was mainly caused by EBV followed by HSV, CMV and
VZV [70]. Recently, encephalitis caused by adenovirus is increasing [69]. The incidence of viral encephalitis after allo-HSCT was 1.2% in a retrospective study [69]. Our results revealed that the incidence of herpesviruses–associated encephalitis/meningitis was 6.3% [70]. In the recipients of allo-HSCT, viral encephalitis/meningitis usually occurs within 100 days post-transplantation. Clinical manifestations of viral encephalitis/meningitis are diverse, including fever, changes of consciousness, seizures, palsy of brain nerves and psychiatric disorders; but meningitis is not common compared with healthy population [69]. The mortality of viral encephalitis/meningitis ranges from 0% to 80%, depending on virus types and timing of diagnosis and treatment [69,71].

Gastroenteritis
Rotavirus and norovirus are considered major causes of viral gastroenteritis. Currently, adenovirus and CMV are increasingly recognized as important pathogens of viral gastroenteritis in the recipients of allo-HSCT. Astrovirus-associated gastroenteritis which usually occurs in children is rarely observed in the recipients of allo-HSCT [72]. Few data are available on the incidence of viral gastroenteritis after allo-HSCT. Van Kraaij et al. documented that 19% of HSCT recipients (including allo- and auto-HSCT) developed viral gastroenteritis [73]. Fortunately, the mortality caused by rotavirus and norovirus-related gastroenteritis is rare [74-77]. The most common clinical manifestation of viral gastroenteritis is diarrhea, followed by vomiting and nausea. Rotavirus and norovirus infections are seasonal with a peak incidence in winter. Most of the patients acquire the viruses from community [74,77]. The median onset time of adenovirus and CMV gastroenteritis are 60–90 days after transplantation, and usually associated with acute GVHD [76,78].

Hepatitis
Viral hepatitis is the third cause of hepatic impairment in the recipients of allo-HSCT, and usually occurs in 3–6 months after transplantation [79]. The most frequent pathogens of viral hepatitis are hepatitis B virus (HBV) and hepatitis C virus (HCV) [80,81]. Besides, other viruses such as CMV and HSV may also result in hepatitis [24,25]. Hepatitis B and C can be caused by either virus reactivation or blood transmission. Since the carriage rates of HBV and HCV vary in different regions, the incidence of viral hepatitis varies [81,82]. Increasing virus loads in blood is valuable for diagnosis. Of note, the diagnosis of viral hepatitis should be based on exclusion of other transplant complications (e.g., sinusoidal obstruction syndrome [SOS] and GVHD). Attributed to effective prophylaxis and antiviral treatment, the mortality of hepatitis B and C is low [81,83].

Cystitis
Post-transplant cystitis usually present with hemorrhagic cystitis (HC). According to onset time, HC is divided into early-onset HC (within 48 hours of conditioning) and late-onset HC (occurring after 48 hours). Early-onset HC is often due to the toxicity of conditioning regimen such as cyclophosphamide. It is reported that 11.6–42% of patients develop late-onset HC after transplantation [84,85]. Late-onset HC was considered to be related with reactivation of latent BK virus (BKV), but this association remains controversial [86,87]. Some studies suggested that acute GVHD might increase the risk of HC [87,88]. Recently, adenovirus and CMV were suggested to be associated with late-onset HC [88,89].

PTLD
PTLD is a life-threatening complication following allo-HSCT. Approximately 90% of PTLD result from EBV-driven B cell proliferation poorly controlled by a weakened immune response. Recent data implicated that CMV and HHV-6 might contribute to the development of PTLD [90,91]. The incidence of PTLD varies from 0.5% to 22%, depending on the number of risk factors [3,68,92-94]. In the recipients of allo-HSCT, most of PTLD occur within 1 year post-transplantation, reaching a peak incidence within 3 months [95-97]. Isolated nodal involvement is the most common presentation. About 20% of patients present with extranodal involvement, and isolated extranodal involvement is not rare [93,96,98-100]. Clinical presentations of PTLD depend on location and the degree of organ involvement. PTLD with extranodal involvement usually have poor outcome. The mortality of PTLD is 50-64% [68,94]. Delay of diagnosis and treatment is associated with a high mortality (>90%) [96,101].

Other viral diseases
Bone marrow suppression is common in the recipients of allo-HSCT. Graft failure is a fatal complication after transplantation. Several viruses, such as CMV, EBV, HHV-6 and adenovirus have been recognized the causes of bone marrow suppression and graft failure [24,25,39,102]. The diagnosis of virus-associated graft failure should be based on pancytopenia, bone marrow hypoplasia, detection of virus together with exclusion of GVHD, rejection and relapse [102].

Common viruses in allo-HSCT recipients
Herpesviruses
The known herpesviruses resulting in human diseases include α- (HSV and VZV), β- (CMV, HHV-6, -7) and γ-herpesviruses (EBV and HHV-8). Herpesvirus infections are usually asymptomatic or subclinical in immunocompetent population. The virus becomes latent in infected cells after primary infection. When immune system is
disordered or deficient, latent viruses may reactivate and result in symptomatic infections, even fatal complications [24,25]. The diagnostic methods of herpesvirus infections were summarized in Table 2.

**HSV**

Up to 80% of the healthy population have history of HSV-1 and HSV-2 infections [25]. HSV-1 infection is more common than HSV-2. After primary infection, the virus becomes latent in the neuronal cells. Historically, 80% of HSV-seropositive patient developed reactivation after allo-HSCT without antiviral prophylaxis [104]. Fortunately, the incidence of HSV reactivation has now decreased to 0-3% because of prophylactic acyclovir [56,105]. HSV causes a spectrum of diseases, such as herpes, oesophagitis, bone marrow suppression, respiratory tract diseases, hepatitis and encephalitis in the recipients of allo-HSCT [25]. Due to the high rate of HSV reactivation, prophylactic oral acyclovir has been administered routinely in allo-HSCT recipients. Intravenous acyclovir should be considered for patients with poor drug absorption [17,106]. Valacyclovir is an alternative prophylactic agent with good bioavailability [107-109]. Acyclovir is recommended as the therapy for severe mucocutaneous or visceral HSV disease in transplant recipients [25]. Valaciclovir and famciclovir are considered as alternatives for less serious manifestations of HSV diseases [25]. The recommended drug for acyclovir-resistant HSV is foscarnet [17]. Cidofovir might be effective to treat HSV infection which is resistant to both acyclovir and foscarnet [110].

**VZV**

Varicella caused by primary VZV infection is a common childhood disease. After primary infection, VZV establishes latency in the dorsal root ganglia in immunocompetent host. The reactivation of VZV results in herpes zoster [111,112]. In the recipients of allo-HSCT, VZV is also an important cause of viral encephalitis. VZV immunization is advocated in recipients without a history of varicella. Varicella vaccine has been shown to be safe in children with leukemia, but few data are available in transplant recipients [106]. Besides, vaccination of VZV-seronegative individuals who may be in contact with the patients during transplantation should be done [25]. Zoster immune globulin (ZIG) and varicella-zoster immune globulin (VZIG) are passive antibody prophylaxis in seronegative recipients after exposure to varicella [113]. Acyclovir and valacyclovir prophylaxis were proven effective in several trials [9,114-117]. Antiviral therapy with acyclovir is recommended in the treatment of VZV infection [25]. Acyclovir has been shown to reduce the progression and dissemination of VZV infection [118,119]. Treatment with brivudin or famiciclovir is effective in immunocompromised population [120,121]. Foscarnet and cidofovir are alternative agents against acyclovir-resistant VZV infection [122].

**CMV**

CMV infects 70-80% of the healthy individuals and establishes latency in peripheral blood monocytes and tissue macrophages. Till now, CMV remains one of the most important viruses and causes of death in the recipients of allo-HSCT. CMV-associated end-organ diseases include pneumonia, enteritis, hepatitis, retinitis and encephalitis, and so on; CMV syndrome is defined as CMV-associated fever without sign of CMV end-organ disease [24]. Majority of CMV infections are caused by reactivation of virus which usually occurs within 3 months post-transplantation [8,24,78]. Approximately 75% of CMV-seropositive recipients develop CMV reactivation, and 20-30% of these patients develop CMV disease without intervention [17,24]. Preemptive therapy based on CMV antigenemia or DNA-emia significantly reduces the development of CMV disease in allo-HSCT patients [24,123]. However, the mortality of CMV disease is more than 50% even with treatments [67,124]. The diagnosis of CMV infection includes CMV viremia, CMV syndrome and CMV end-organ disease [24]. Historically, CMV antigen (pp65) detection was widely used in diagnosis of CMV infection. Recently, PCR is replacing antigenemia assay to be the preferred diagnostic method due to higher sensitivity [24,103].

Preemptive therapy based on CMV viremia has become the standard prevention of CMV diseases after transplantation [24]. The first-line preemptive therapy is ganciclovir with a minimum duration of 2 weeks depending on whether CMV is detected at the end of the course [24,125,126]. The main side effect of ganciclovir is bone marrow suppression which results in the increase of bacterial and fungal infection [127,128]. Valganciclovir is an alternative with good bioavailability [129-131]. Foscarnet and cidofovir are the second-line prophylactic agents considering of drug-associated toxicity [24].

Ganciclovir is the first-line treatment of CMV diseases. The recommended therapy of CMV pneumonia is a

### Table 2 Laboratory diagnosis of herpesviruses

| Viruses | Methods |
|---------|---------|
| HSV     | PCR(preferred); antigen detection [25] |
| VZV     | PCR(preferred); Immunofluorescent-antibody staining [25] |
| CMV     | PCR(preferred); CMV antigen (pp65) detection [24,103] |
| EBV     | PCR; immunohistochemistry or in situ hybridization to detect EBV in biopsy specimens [25] |
| HHV6-8  | PCR [24] |
combination of intravenous ganciclovir and high dose immune globulin [24,124,132]. In view of toxicity and effective rate, cidofovir and foscarnet are used as second-line therapy of CMV diseases [24]. Ganciclovir resistance is uncommon and usually mediated through mutations in the UL97 gene. Cidofovir is used in the treatment of CMV disease which is resistant to ganciclovir and foscarnet, with an effective rate of 50% [133]. Since it has been known that specific immune response to CMV is important to control reactivation, CMV-specific CTL has been used in prophylaxis and treatment of CMV viremia in several studies [50,51,134]. Leen et al. reported that the response rate of CMV-specific CTL was 73.9% in the treatment of CMV diseases after allo-HSCT [50].

**EBV**

Approximately 90% of healthy adults have been infected by EBV. After primary infection, EBV is latent in B cells (6, 8). Primary EBV infection or reactivation usually induces asymptomatic infection or infectious mononucleosis in immunocompetent people. However, EBV results in a spectrum of diseases in the recipients of allo-HSCT, ranging from fever, end-organ disease (pneumonia, encephalitis/myelitis, and hepatitis) to PTLD in several studies [50,51,134]. Leen et al. reported that the response rate of CMV-specific CTL was 73.9% in the treatment of CMV diseases after allo-HSCT [50].

Preemptive therapy based on EBV-DNA loads in blood and risk factors for EBV disease has yielded good results [25]. Preemptive therapy is now developing mainly in two directions: adoptive cellular immunotherapy. The results revealed that this combined with rituximab [148]. To date, there are no randomized trials to compare the efficacy between rituximab alone and rituximab combined with chemotherapy. Trappe et al. [148] suggested that sequential first-line treatment with rituximab followed by chemotherapy is more efficacious than first-line rituximab monotherapy followed by chemotherapy at progression or relapse. In our study, we introduced a sequential therapeutic strategy that is rituximab-based treatments followed by adoptive cellular immunotherapy. The results revealed that this strategy might elevate response rate and decrease the relapse rate. Besides, this strategy might overcome the drawback of long time frame to product EBV-CTL and reduce the risk of GVHD caused by DLI. It remains a matter of discussion that whether histology subtypes of PTLD affect the outcome of rituximab-based treatments [148,149]. The prognosis of PTLD with extranodal or multi-organ involvement is dismal compared with isolated nodal involvement [34,150]. Some studies suggested that intrathecal rituximab is efficacious against PTLD with CNS involvement [151-153]. Other therapeutic options include local radiotherapy and operation, which is mainly for the patients with significant compression symptoms [145].
Clinical data on EBV fever and end-organ diseases are quite limited. Rituximab seems efficacious to treat EBV fever, with a response rate of 100% [4,154]. The treatment strategies of EBV end-organ diseases are similar with PTLD. However, the efficacy of rituximab monotherapy in patients with end-organ diseases seemed poorer than those with PTLD [4].

**HHV6-8**

Approximately 50% of recipients develop HHV-6 reactivation after transplantation [28,30]. HHV-6 diseases include encephalitis, interstitial lung disease and delayed engraftment [24,31]. Two small-sampled studies suggested that ganciclovir might be effective to prevent HHV-6 reactivation in allo-HSCT recipients [155,156]. However, no widely accepted prophylactic strategy is recommended considering of the drug toxicity and the low incidence of HHV-6 diseases [24]. Both ganciclovir and foscarnet were reported to be effective against HHV-6 diseases [157].

HHV-7 infection/reactivation is infrequent in the recipients of allo-HSCT, and little information about HHV-7 diseases is available. Therefore, prophylaxis and treatment of HHV-7 infection remain unclear [24].

HHV-8 is recognized as the cause of Kaposi’s sarcoma in human immunodeficiency virus (HIV) infected patients [158]. HHV-8 infection is rare in the recipients of allo-HSCT, and usually results in non-malignant diseases such as hepatitis, bone marrow suppression [159,160]. Currently, clinical data on prevention and treatment of HHV-8 diseases after allo-HSCT are based on case reports. Cessation of immunosuppressants and foscarnet were used for treatment, and the efficacy requires further study [161,162].

**CARVs**

CARVs, including orthomyxo- (influenza virus), paramyxovirus (RSV, PIV, HMPV), picorna- (human rhinovirus [HRhV]), coronaviruses (HCoVs), human bocavirus (HBoV), and polyomaviruses, are important pathogens of respiratory tract infections in the recipients of allo-HSCT, [26]. Significant overlap in clinical manifestations is observed in CARVs infections, and atypical presentations are common. Table 3 summarized the diagnostic methods and epidemiology of CARVs infections in the recipients of HSCT. Antigen detection has a good specificity and a short turn-around time of several hours, but a lower sensitivity compared with PCR [59]. Currently, PCR for detection of virus nucleic acid is preferred in diagnosis [26].

Infection control is the mainstay of prevention against CARVs disease. Healthcare facilities and infection control measures, including isolation and strict protection measures for healthcare workers and contacts, should be applied to HSCT recipient [26,168]. Besides, recipients and contacts should adhere to good personal hygiene. Recipients should avoid contact with individuals with CARVs respiratory infections in the hospital and the community [26,168].

**RSV**

RSV is one of the most common respiratory pathogens in most series including HSCT recipients. Limited data are available on prevention of RSV infection. In some studies, treating upper respiratory tract disease was effective to reduce the progression to pneumonia and improve the outcome [26,163,164]. But some other reports did not confirm this result [169,170]. Aerosolized ribavirin with or without RSV-specific immunoglobulin or intravenous immunoglobulin has been used to treat RSV pneumonia, with the 30-days survival of approximately 60% [19,54,64,163,171]. Treatment started before respiratory failure is associated with improved outcome [19,54,64]. Intravenous ribavirin is less effective but increases the side effects [55]. The efficacy of palivizumab (an RSV-specific monoclonal antibody) in HSCT recipients is not well defined [172,173].

**PIV**

PIV infection occurs throughout the year, with the highest incidence in July and September [166]. The prophylactic and therapeutic strategies against PIV infection remain a matter of discussion. A large-sampled retrospective analysis suggested that aerosolized ribavirin with or without intravenous immunoglobulin did not improve the outcome of PIV pneumonia [165]. Elizaga et al. documented that the effective rate of aerosolized ribavirin therapy was 100% in the treatment of upper tract infections, whereas only 25% of patients with PIV pneumonia survived [166].

**Influenza virus**

To prevent influenza after transplantation, the European guidelines recommended that vaccination should be performed in HSCT recipients with seasonal influenza vaccine [59]. Meanwhile, vaccination of healthcare workers and close contacts with HSCT recipients is advocated [59]. Prophylaxis with oseltamivir seems useful after exposure and during the period of influenza circulation [59,174]. M2 inhibitors, amantadine and rimantidine have no longer been used for treatment due to widespread resistance [175,176]. Neuraminidase inhibitors (oral oseltamivir or inhalational zanamivir) are now the most widely used therapeutic agents for influenza, with an effective rate of 46-100% [21,177,178]. Intervention initiated within 48 hours of symptom onset was associated with reduced risk both for pneumonia and the need for intensive care [21,179].

**Other CARVs**

At present, respiratory infections after HSCT caused by HCoV, HMPV and HRhV have been increasingly
recognized. In our recent study, HCoV was found in 16.2% of the recipients within 6 months after HSCT, including 12% of LRTI; HMPV and HRhV was found in 5.4% and 2.7% of the recipients, respectively. The efficacious prevention and treatment of HMPV infections have not been well described. Ribavirin and/or intravenous immunogloblin were used to treat HMPV pneumonia in several studies but the efficacy was not defined [26,180]. The prevention and treatment strategies of HRhV are limited by the lack of antiviral agents and clinical trials. There are no recommendations on prophylaxis and treatment due to absence of effective antiviral agents and appropriate clinical studies [26].

**Adenovirus**

Adenovirus is increasingly recognized as an important pathogen in immunocompromised individuals, especially in the recipients of allo-HSCT. Adenovirus infection may arise from either reactivation of latent virus or acquisition from community. Contrary to self-limited infection in most immunocompetent individuals, adenovirus causes lethal end-organ or systemic diseases in immunocompromised patients [39]. The incidence of adenovirus infection ranges from 0-6% in adult allo-HSCT recipients, and half of these patients developed adenovirus-associated diseases [18,22]. Adenovirus diseases include respiratory tract disease, gastroenteritis, encephalitis, myocarditis, nephritis and multiple organ involvement [18,22]. The mortality was reported as high as 100% in adenovirus pneumonia [39] and 61% in disseminated disease [181]. Now, PCR is the standard diagnostic method of adenovirus infection [39]. Other diagnostic approaches include viral culture and antigen detection [39].

Strict isolation and hygiene measures are advocated in patients shedding the adenovirus to prevent horizontal transmission and nosocomial outbreaks. Bordigoni et al. [182] suggested cidofovir or DLI seemed encouraging approaches to prevent adenovirus diseases, whereas ribavirin and vidarabin were ineffective.

The efficacy of ribavirin is controversial in the treatment of adenovirus diseases [182-184]. Several studies documented that cidofovir was efficacious against adenovirus [75,76,182,185]. Considering of the insufficient immune response to control adenovirus reactivation in the patients, adenovirus-specific CTL seems a promising therapy [186,187]. Leen et al. reported that the effective rate of adenovirus-specific CTL was 77.8% in the recipients of allo-HSCT [50]. In addition, reduction of immunosuppressants is recommended for prophylaxis and treatment if possible [18].

**Gastroenteritis viruses**

Rotavirus and norovirus are important pathogens of viral gastroenteritis. The incidence of rotavirus infection is 6.7-11.5% in HSCT recipients, and death is rare [73,74]. Antigen detection as well as PCR is used in diagnosis of rotavirus infection. At present, norovirus as a cause of gastroenteritis after allo-HSCT is not well recognized [188]. In pediatric HSCT recipients, the incidence of norovirus-associated gastroenteritis was reported 12.9% and no norovirus-associated mortality was observed [77]. Detection of norovirus RNA by PCR is the main diagnostic evidence. Till now, little information is available about prevention and treatment of rotavirus and norovirus in the HSCT population. Oral immunoglobulin and nitazoxanide have been used in some studies [74].

**Hepatitis viruses**

Among hepatitis viruses, HBV and HCV are important causes of hepatic impairment in the recipients of allo-HSCT. Hepatitis virus-positive donor should be avoided if alternatives exist.

For HBV-negative recipients, pre-transplant vaccination and HBV-specific immune globulin should be considered if the donors are HBV surface antigen positive. For HBV-positive recipients, administration of antiviral agents (i.e. lamivudine, fosciclovir, Entecavir and adefovir) pre- and post-transplantation is advocated to reduce HBV replication [189,190].

Administration of ribavirin and interferon should be considered to decrease or clear the viral loads before transplantation in donors and recipients who are HCV infected.

---

**Table 3 CARVs infections after HSCT**

| Viruses     | Diagnostic methods | Incidence of infection | Progression to LRTI | Mortality with LRTI |
|-------------|--------------------|------------------------|---------------------|---------------------|
| RSV         | PCR(preferred); Antigen detection; culture | 2.2-5.8% [27,64,163]   | 17-84% [19,164]     | 7-83% [19,164]     |
| PV          | PCR(preferred); Antigen detection; culture | Up to 17.9% [19,165]   | 50%[19,165]         | Up to 75% [166]    |
| Influenza virus | PCR(preferred); Antigen detection; culture | 1.7-9.0% [19,21,23]    | 18-44% [19,21,23]   | 5-37% [19,21,23]   |
| HMPV        | PCR(preferred); Antigen detection; culture | 2.5-9% [26]            | 21-40%              | 33-40%              |
| HRhV        | PCR(preferred); culture | 22.3% [26]             | <10% [26]           | ?                   |
| HCoV        | PCR                | 2.1% [167]             | ?                   | ?                   |
| HBoV        | PCR                | ?                      | ?                   | ?                   |

?, absence of significant studies.
positive [17,191]. Interferon with or without ribavirin is used for treatment of hepatitis C [192,193].

Polyomaviruses
JC virus (JVC) which belongs to polyomavirus family is known a pathogen of progressive multifocal leukoencephalopathy (PML) in patients with HIV infection. Reports of PML are quite rare in the recipients of allo-HSCT [194]. Currently, treatment and prevention of JCV in HSCT recipients remain unclear. Treatments consisting of reduction of immunosuppressants, cidofovir and sorafenin-reuptake inhibitor as well as of JCV-specific CTL infusion were demonstrated to produce a favorable clinical outcome [195]. As mentioned, BKV as a member of polyomavirus family is one of the causes of HC in allo-HSCT recipients. It is reported that ciprofloxacin and other fluoroquinolones may be useful to prevent BKV reactivation [195]. Cidofovir has been used in the treatment of BKV-associated HC [196,197].

Conclusion
Viral diseases are important complications after HSCT. Development of viral diagnostics improves the early diagnosis and increases the diagnostic rate of some newly discovered or uncommon viruses in allo-HSCT recipients. Based on the pathogenesis of viral diseases, prophylaxis, especially preemptive therapy can limit reactivation of some latent viruses. Immunotherapeutic strategies to restore virus-specific immunity are attractive methods in the treatment of viral diseases.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
The manuscript is derived from literature summarizing reports prepared by RL and QFL. Both authors wrote the manuscript and have read and approved the final version.

Acknowledgements
This project was supported by the National High Technology Research and Development Program of China (863 Program) (2011AA020105), the National Natural Science Foundation of China (81270647, 81000231, 81300445) and Project of Guangzhou Science and Technology Plan (11A72121174).

Received: 26 October 2013 Accepted: 30 November 2013
Published: 17 December 2013

References
1. Gratwohl A, Brand R, Frassoni F, Rocha V, Niedenwieser D, Reusser P, Erni E, Cordonnier C. Cause of death after allogeneic hematopoietic stem cell transplantation (HSCT) in early leukemias: an EMAT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2006, 36(9):757–769.
2. Ozdemir E, Saliba RM, Chaplin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Komblau SM, Anderlini P, et al: Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007, 40(3):125–136.
3. Hale G, Waldmann H: Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998, 91(8):3079–3083.
4. Xuan L, Jiang X, Sun J, Zhang Y, Huang F, Fan Z, Guo X, Dai M, Liu C, Yu G, et al: Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Transplantation 2013, 96(5):560–566.
5. Lv M, Huang XJ: Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol 2012, 5:10.
6. Storch GA: Diagnostic virology. Clin Infect Dis 2000, 31(3):739–751.
7. Watzinger F, Ebner K, Lion T: Detection and monitoring of virus infections by real-time PCR. Mol Aspects Med 2006, 27(2–3):254–298.
8. Saini DG, Gunduz E, Kasifoglu N, Akay OM, Us T, Gabbus Z: Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients. Adv Ther 2013, 30(5):784–791.
9. Klein A, Miller KB, Sprague K, Desjardins JA, Snyderman DR: A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transplant 2011, 46(2):294–299.
10. Goodrich JM, Mori M, Gaines CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmstrong B, Meyers JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991, 325(23):1601–1607.
11. Green ML, Leisening W, Stachel D, Pergam SA, Sandmaier BM, Wald A, Corye L, Boehm M: Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic stem cell transplantation. Blood Marrow Transplant 2012, 18(11):1687–1699.
12. Doubrovina E, Offaz-Sozmen B, Prockop SE, Kerman NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, et al: Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012, 119(11):2644–2656.
13. Mackinnon S, Thomson K, Verfu¨rth S, Peggs K, Lowdell M: Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008, 40(1):63–67.
14. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillo AP, Small TN, et al: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330(7):1185–1191.
15. Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N: Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol 2012, 1(1):13.
16. Loren AW, Porter DL, Stadtmauer EA, Tsai DE: Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003, 31(3):145–155.
17. Ljungman P: Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 2002, 118(1):94–57.
18. Chakrabarti S, Nautner V, Osman H, Collingham KE, Fegan CD, Klappe PE, Moss PA, Milligan DW: Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002, 100(5):1619–1627.
19. Nichols WG, Gooley T, Boechl H: Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001, 7(Suppl):115–122.
20. Martino R, Porras RP, Rabella N, Williams Jv, Ramila E, Mangall N, Labeaga R, Crowe J, Coll P, Sierra J: Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005, 11(10):781–796.
21. Nichols WG, Guthrie KA, Corey L, Boechl H: Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004, 39(9):1300–1306.
22. Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak Gv, Mcauliffe T, Camitta B, Horowitz MM, Bunin N, et al: Increasing incidence
European Blood and Marrow Transplantation Group. Transplantation 1999, 68(10):1486–1491.

80. Lalaz G, Rond D, Shouval D: Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136(5):699–712.

81. Locasciulli A, Bruno B, Alessandrini EP, Meloni G, Arcese W, Bandini G, Gasabbi V, Rotoli B, Morra E, Maiolino L, et al: Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003, 31(4):295–300.

82. Cui Y, Ji J: Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol 2013, 28(8 suppl):S7–10.

83. Strasser SL, Myerson DS, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Kim S, Flowers ME, McDonald GB: Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999, 29(6):1893–1899.

84. Tsuibo K, Kishi K, Ohmachi K, Yasuda Y, Shimizu T, Inoue H, Matsumoto M, Hatton K, Yoshida Y, Watanabe S, et al: Multivariate analysis of risk factors for hemorrhagic cysts after haemopoietic stem cell transplantation. Bone Marrow Transplant 2003, 32(9):903–907.

85. Kooos RQ, Boelens JJ, de Jong TP, Versluis B, Bierling S: Hemorrhagic cysts in a cohort of pediatric transplantations: incidence, treatment, outcome, and risk factors. Biol Blood Marrow Transplant 2013, 19(8):1263–1266.

86. Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P, Arthur RB, Jones RJ: Association of BK virus with failure of prophylaxis against hemorrhagic cysts following bone marrow transplantation. J Clin Oncol 1995, 13(3):1103–1109.

87. Leung AY, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R, Kwong YL: Clinicopathological features and risk factors of clinically overt haemorrhagic cysts complicating bone marrow transplantation. Bone Marrow Transplant 2002, 29(9):509–513.

88. Han TT, Xu LP, Liu OH, Liu KY, Fu HK, Zhao XY, Zhao XS, Huang XJ: Cytomegalovirus is a potential risk factor for late-onset hemorrhagic cysts following allogeneic hematopoietic stem cell transplantation. Ann J Hematol 2013. doi: 10.1002/ajh.23584.

89. Akiyama H, Kurutsu T, Sakashita C, Inoue T, Mori S, Ohashi K, Tanikawa S, Sakamaki H, Onozawa Y, Chen Q, et al: Adenovirus is a key pathogen in hemorrhagic cysts associated with bone marrow transplantation. Clin Infect Dis 2001, 32(9):1325–1330.

90. Tsoa SY, Chang KC, Chen YP, Yeh YM, Su WC, Chen TY: Cytomegalovirus and Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2011, 90(11):113–114.

91. Manes S, Beiring MC, Linden P, Wilson J, Tome-Cinhoros J, Kusne S, Dummer S, Ho M: Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997, 176(6):1462–1467.

92. Cornoli P, Basso S, Zecchi M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretti A, Labirio M, Prati P, et al: Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007, 7(10):2517–2525.

93. Reeder DM, Ho M: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1998, 92(2):520–529.

94. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, Levitsky V, Reimer MR: The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006, 91(8):1059–1067.

95. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, et al: Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Biol Blood Marrow Transplant 1999, 5(4):220–227.

96. Meier E, Comelissen JJ: Epstein-Barr virus-associated lymphoproliferative disease following allogeneic hematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008, 15(5):576–585.

97. Chang KY, Hazlett LJ, Godder KT, Abhyankar SH, Christensen NP, van Rhee F, Lee CG, Bridges K, Paranth RN, Henslee-Downey PJ: Epstein-Barr virus-associated...
B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Bone Marrow Transplant 2001, 28(12):1117–1123.

98. Nozolli C, Bartolozzi R, Guidi S, Orsi A, Vannucchi AM, Leoni F, Bosi A: Epstein-Barr virus-associated post-transplant lymphoproliferative disorder with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006, 47(1):167–169.

99. Shimizu H, Saitoh T, Koya H, Yuzuihara A, Hoshino T, Hatsumi N, Takada S, Nagaki T, Nojima Y, Sakura T: Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol 2011, 94(3):495–498.

100. Kittan NA, Beier F, Kuz K, Niller HH, Egger L, Jilg W, Arendessen R, Holler E, Hildebrandt GC: Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transp Infect Dis 2011, 13(S2):524–530.

102. Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus infections and disease in transplant recipients. Clin Infect Dis 2002, 34(8):1094–1097.

103. Ljungman P, Hakki M, Boechl M: Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010, 24(3):339–373.

104. Meyers JD, Narayan N, Thomas ED: Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980, 142(3):338–346.

105. Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Machishima T, Terasako K, Kimura S, et al: Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2013, 15(4):457–465.

106. Dykewicz CA, Kaplan JE: Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000, 49(RR-10):1–125. E1-E7.

107. Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Hoglund M, Ljungman P, Wilczek H, Gahrton G, Lundgren G, Lonnqvist B: Prevention of localized dermatomal herpes zoster in immunocompromised patients. J Antimicrob Chemother 2011, 66(5):1215–1221.

108. Niesvold B, Charleson J, Lin and Liu: Journal of Hematology & Oncology 2013, 6:94
http://www.jhonline.org/content/6/1/94
Page 12 of 14
transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001, 97(2):388–392.

134. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, Byth K, Dubosq MC, Shaw PJ, Micklethwaite KP, et al: Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013, 121(19):3745–3758.

135. Liu Q, Xuan L, Liu H, Huang F, Zhou H, Fan Z, Zhao K, Wu M, Xu L, Zhai X, et al: Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 2013, 88(3):550–553.

136. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmen MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM: Frequent monitoring of Epstein-Barr virus DNA load in unfractured whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001, 97(2):1165–1171.

137. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RI, et al: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115(5):925–935.

138. Peric Z, Cahu X, Chevallier P, Brisset E, Malaud F, Guillaume T, Delaunay Ayari S, Dubrulle V, Le Gouill S, et al: Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia 2011, 25(8):932–938.

139. Penrime SP, Hemmings O, Small T, Suarez F, O'Reilly B, Rouland F, Fongerloth J, Askin M, Le Cuyer, and Mentzer SJ, et al: A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007, 109(6):2571–2578.

140. Faller DV, Mentzer SJ, Penrime SP: Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 2001, 13(5):360–367.

141. Elston RL, Andreasen C, Aqui NA, Ahya VN, Bloom DR, Brozena SC, Othoff KM, Schuster SJ, Nasta SD, Stadtmueller MA, et al: Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006, 6(3):569–576.

142. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe PC, Rubenstein JL, Fridlyand J, Abrey LE, et al: Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 29(7):595–598.

143. Karim R, Engelhard D, Tager G, Per R, Finkel N: Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transplant Proc 2002, 4(1):10–16.

144. Zerr DM, Gupta D, Huang ML, Carter R, Corey L: Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2002, 15(4):309–317.

145. Grant S, Gaspar C: Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011, 24(2):295–301.

146. Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, Trovato R, Donelli F, Donelli A, Maiorana A, Marasca R, et al: Bone marrow failure associated with human herpes virus 8 infection after transplantation. N Engl J Med 2000, 343(19):1378–1385.

147. Cuzzola M, Iretta G, Iacopino O, Gazzard B, Mesina G, Consolo G, Iacopino P, Morabito F: Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation. Clin Infect Dis 2003, 37(1):e102–e106.

148. Small TN, Casson A, Malak SF, Boulad F, Kerigh JD, Stiles J, Ushay HM, Schellinger K: Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29(6):321–327.

149. Shah JN, Chemaly RF: Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011, 117(10):2755–2763.

150. Nichols W, Corey L, Gooley T, Davis C, Boeckh M: Parainfluenza virus infections after hematopoetic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2007, 108(2):319–331.

151. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K: Parainfluenza virus 3 infection after stem cell transplantation: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001, 33(2):413–418.

152. Milano F, Campbell AP, Guthrie KA, Kuyers E, Englund JA, Corey L, Boeckh M: Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood 2010, 115(10):2085–2094.

153. Tomblin M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15(1):1143–1238.
hematologic malignancies and human stem cell transplant recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006, 85(5):278–287.

170. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, Kupfers J, Kim H, Gramm J, Whitley R: Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007, 44:249–250.

171. DelVincenzo JP, Hirsch RL, Fuentes RJ, Top FJ: Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant 2000, 25(1):161–165.

172. de Fortbrune FS, Robin M, Porcher R, Sicieux C, de Latour RP, Ferry C, Rocha V, Bouchet K, Devergie A, Bergeron A, et al: Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007, 45(8):1019–1024.

173. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L: Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2007, 295(3):530–534.

174. Vu D, Peck AJ, Nichols WG, Varley C, Englund JA, Corey L, Boeckh M: Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case–control study. J Infect Dis 2007, 45:2187–193.

175. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI: Amantadine and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998, 26(6):1418–1424.

176. Klimov AI, Rocha E, Hayden FG, Shalt P, Roumimil LF, Cox NJ: Prolonged shedding of amantadine-resistant influenza A viruses in symptomatic immunocompromised patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995, 172(3):1352–1355.

177. Johny AA, Clark A, Price N, Carrington D, Oashill A, Marks DI: The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 29(2):113–115.

178. Fraaij PL, van der Vries E, Beersma MF, Riezebos-Brilman A, Niesters HG, van der Eijk AA, de Jong MD, Reis MD, Harrevoets AM, Ridwan Bu, et al: Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011, 204(5):777–782.

179. Ljungman P, Andersson J, Aschan J, Bjorkstrand B, Hagglund H, Lonnqvist B, Ringden O, Wiianinski J: Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis 1996, 23(1):167–169.

180. Gardini C, Gallimberti M, Lucarelli G, Polchi P, Angelucci E, Barociani D, Erer B, Gaviez D, Piga A, Di Gregorio F, et al: Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for hematogenous beta-thalassemia. Bone Marrow Transplant 1997, 20(8):767–772.

181. Ljungman P, Johansson N, Aschan J, Gaumann H, Lonnqvist B, Ringden O, Sparreli E, Sonnerborg A, Wiianinski J, Gahton G: Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995, 86(4):1614–1618.

182. Balduzzi A, Lucchini G, Hirsch HH, Basso S, Cioni M, Rovelli A, Zincone A, Grimaldi M, Corti P, Bonannori S, et al: Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2011, 46(7):987–992.

183. Jang YJ, Park JH, Kim BH, Kim BJ, Park JH, Park JH, Park JH: Cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 39(12):783–787.

184. Rend S, Raffegest S, Chen X, Schendel D, Kolb HJ, Roskrow M: Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant 2001, 27(1):53–64.

185. Riddle C, Paul JP, Benjamin R, Gallimore CJ, Xery J, Gary J, Peggy KS, Morris EC, Thomson KJ, Ward KN: Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009, 49(7):1061–1068.

186. Endo T, Sakai T, Fujimoto K, Yamanoto S, Takahashi H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K: A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2001, 27(4):433–436.

187. Lau GK, Liang R, Wu PC, Lee CK, Lim WL, Au WY: Use of famciclovir to prevent HBV reactivation in HBSAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998, 28(3):359–368.

188. Ljungman P, Anderson J, Aschan J, Bjerklund A, Hagglund H, Lonnqvist B, Ringden O, Wiianinski J: Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis 1996, 23(1):167–169.